ADVERTISEMENT
CAR T Cell Adds Scorpion Venom to Tackle Tumor Heterogeneity
CAR T Cell Adds Scorpion Venom to Tackle Tumor Heterogeneity
A newly engineered CAR T cell that incorporates a peptide isolated from the venom of the deathstalker scorpion has broad brain tumor–binding capabilities that will be investigated in an upcoming clinical trial.
CAR T Cell Adds Scorpion Venom to Tackle Tumor Heterogeneity
CAR T Cell Adds Scorpion Venom to Tackle Tumor Heterogeneity

A newly engineered CAR T cell that incorporates a peptide isolated from the venom of the deathstalker scorpion has broad brain tumor–binding capabilities that will be investigated in an upcoming clinical trial.

A newly engineered CAR T cell that incorporates a peptide isolated from the venom of the deathstalker scorpion has broad brain tumor–binding capabilities that will be investigated in an upcoming clinical trial.

clinical trials, cell & molecular biology, cancer

Cancer Immunotherapist
Jef Akst | Mar 31, 2015 | 1 min read
Scientist to Watch Yvonne Saenger explains recent advances in using biomarkers to identify cancer patients who might benefit most from immunotherapy.
The Little Cell That Could
Megan Scudellari | Jul 1, 2012 | 7 min read
Critics point out that cell therapy has yet to top existing treatments. Biotech companies are setting out to change that—and prove that the technology can revolutionize medicine.
Drugs target cancer stem cells
Bob Grant | Jun 6, 2011 | 1 min read
New compounds are showing promise in targeting subpopulations of cancer stem cells.
ADVERTISEMENT